 CHARLOTTESVILLE, Va., Feb. 23, 2021 GLOBE NEWSWIRE -- Adial Pharmaceuticals, Inc. NASDAQ: ADIL; ADILW Adial or the Company, a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be filing an application for Fast Track with the U.S. Food and Drug Administration FDA for its lead drug candidate, AD04, which is a therapeutic agent for the treatment of Alcohol Use Disorder AUD in persons with certain target genotypes. 